Company profile: Syrrx
1.1 - Company Overview
Company description
- Provider of drug discovery services leveraging high-throughput structural biology, focusing on drug targets validated in human clinical trials and directing efforts toward therapeutics for metabolic diseases, cancer, and inflammation.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Syrrx
Boca Biolistics
HQ: United States
Website
- Description: Provider of hybrid CRO and biobank services, delivering human biospecimens across oncology and other diseases; end-to-end contract research to support development and market approval of diagnostic technologies; CLIA-certified, CAP-accredited reference lab testing; COVID-19 serology and PCR; and oncology research solutions combining clinical research, data analytics, and industry leading clinical and molecular datasets to enable precision medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Boca Biolistics company profile →
Noramco
HQ: United States
Website
- Description: Provider of design, construction, and management services for bulk active pharmaceutical ingredient plants, including a Wilmington, Delaware facility supporting Ortho-McNeil Pharmaceutical's Tylenol with codeine business; expanded through the acquisition of Tasmanian Alkaloids and the addition of an Athens, Georgia site in 1982.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Noramco company profile →
Oncodesign
HQ: France
Website
- Description: Provider of precision medicine-driven oncology preclinical CRO services and biopharmaceutical R&D, developing anticancer therapies and leveraging platforms such as Nanocyclix for selective kinase inhibitors and OncoSNIPER AI for resistant patient stratification. Pipeline includes OPM-101 (RIPK2, IBD), OPM-102 (RIPK2, inflammation-related tumors), and an LRRK2 program (Parkinson’s), plus the IMODI cluster for cancer models and microbiota studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncodesign company profile →
KBI Biopharma
HQ: United States
Website
- Description: Provider of fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally; a leading development and contract manufacturing organization serving the biopharmaceutical industry, working closely with client partners to personalize and rapidly accelerate drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KBI Biopharma company profile →
Catalent
HQ: United States
Website
- Description: Provider of advanced drug delivery technologies and outsourced development, manufacturing, and packaging services for the pharmaceutical, biotechnology, and consumer health industries worldwide. Includes Development & Clinical Services; Oral, Sterile, and Packaging technologies; ProteoSuite Oral; Softgel technologies; inhalation development & analytical; biologics development with GMP analytics; clinical supply services; consumer health products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Catalent company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Syrrx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Syrrx
2.2 - Growth funds investing in similar companies to Syrrx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Syrrx
4.2 - Public trading comparable groups for Syrrx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →